Details of Disease

General Information of Disease (ID: DIS4R2OG)

Disease Name Hyperlipidaemia
Synonyms familial hyperlipoproteinemia; familial hyperlipemia; hyperlipidaemia; hyperlipemia; hereditary hyperlipidemia (disease)
Disease Class 5C80: Hyper-lipoproteinaemia
Definition An instance of hyperlipidemia (disease) that is caused by an inherited modification of the individual's genome.
Disease Hierarchy
DISEOA7S: Lipid metabolism disorder
DIS28TLT: Hyperlipemia
DIS4R2OG: Hyperlipidaemia
ICD Code
ICD-11
ICD-11: 5C80
ICD-10
ICD-10: E78.4, E78.5
Disease Identifiers
MONDO ID
MONDO_0001336
UMLS CUI
C0700623
MedGen ID
675194
SNOMED CT ID
238038003

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 7 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Bezafibrate DMZDCS0 Approved Small molecular drug [1]
Cerivastatin DMXCM7H Approved Small molecular drug [2]
Gemfibrozil DMD8Q3J Approved Small molecular drug [3]
Omega-3-acid ethyl esters 90 DM55TTJ Approved NA [4]
Sitosterol DM05DR0 Approved Small molecular drug [4]
Teriflunomide DMQ2FKJ Approved Small molecular drug [5]
TOCOTRIENOL DM1UE67 Approved Small molecular drug [6]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 Drug(s)
This Disease is Treated as An Indication in 32 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Anacetrapib DMP2BFG Phase 3 Small molecular drug [7]
Dalcetrapib DMKNCVM Phase 3 Small molecular drug [8]
PAMAQUESIDE DM4SKYI Phase 3 Small molecular drug [9]
1-MNA DM5DC3R Phase 2/3 NA [10]
264W94 DMBOL4K Phase 2 Small molecular drug [11]
AEM-28 DMI5TXZ Phase 2 NA [12]
AMP-579 DMJ4GPR Phase 2 Small molecular drug [13]
CRILVASTATIN DMO1ZGX Phase 2 Small molecular drug [14]
Eldacimibe DML7WP0 Phase 2 Small molecular drug [15]
Eniluracil DM96NCR Phase 2 Small molecular drug [16]
FM-VP4 DM3BHJ2 Phase 2 NA [17]
GFT14 DMD3RU8 Phase 2 NA [18]
Granotapide DMMZQ7V Phase 2 Small molecular drug [19]
GSK-256073 DMMAIY2 Phase 2 Small molecular drug [20]
Ibrolipim DMOPWSX Phase 2 Small molecular drug [21]
Implitapide DMTN16K Phase 2 Small molecular drug [22]
Kybiqo DMRC19N Phase 2 NA [23]
MB-07811 DM6JTSZ Phase 2 Small molecular drug [24]
MGL-3196 DM1HC9R Phase 2 NA [25]
S-8921 DMRZA6G Phase 2 Small molecular drug [26]
Sitostanol ascorbyl phosphate DMBV6US Phase 2 NA [27]
SLx-4090 DMM3AI8 Phase 2 Small molecular drug [28]
TA-8995 DMAZHT0 Phase 2 NA [29]
XZK DM27B0F Phase 2 NA [30]
XZK-monascus DMPI6N0 Phase 2 NA [31]
Axitirome DM6L5IP Phase 1 Small molecular drug [32]
CDT-fenofibrate DMKUXB5 Phase 1 NA [33]
GW-409544 DMOE5SZ Phase 1 Small molecular drug [34]
ISIS-ANGPTL3 DM9Y51T Phase 1 Antisense drug [35]
PF-06427878 DMGB32Z Phase 1 NA [36]
SPC5001 DMUPQ70 Phase 1 NA [37]
Turofexorate isopropyl DM36ONA Phase 1 Small molecular drug [38]
------------------------------------------------------------------------------------
⏷ Show the Full List of 32 Drug(s)
This Disease is Treated as An Indication in 39 Discontinued Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Benfluorex DMPNPF0 Withdrawn from market Small molecular drug [4]
Dalvastatin DMZ38EN Discontinued in Phase 3 Small molecular drug [39]
Lapaquistat acetate DMJY9CW Discontinued in Phase 3 Small molecular drug [40]
AVE-0847 DMRYK1C Discontinued in Phase 2 NA [41]
AZALANSTAT DMV1ES3 Discontinued in Phase 2 Small molecular drug [42]
BMS-187745 DMP8SIV Discontinued in Phase 2 Small molecular drug [43]
BMY-21950 DM2NBXR Discontinued in Phase 2 Small molecular drug [44]
CI-976 DMBO28J Discontinued in Phase 2 Small molecular drug [45]
CL-283796 DM7LIDT Discontinued in Phase 2 NA [46]
CRD-5 DMVU4A5 Discontinued in Phase 2 NA [47]
E-5324 DM562BM Discontinued in Phase 2 Small molecular drug [48]
Eflucimibe DMZXRF2 Discontinued in Phase 2 Small molecular drug [49]
FL-386 DMUQN83 Discontinued in Phase 2 Small molecular drug [50]
GLENVASTATIN DMT1LQS Discontinued in Phase 2 Small molecular drug [51]
KRP-101 DMBU9O4 Discontinued in Phase 2 NA [52]
KRP-297 DM9VHZC Discontinued in Phase 2 Small molecular drug [53]
NS-220 DMQ82T5 Discontinued in Phase 2 Small molecular drug [54]
OCO-1112 DM8C6HE Discontinued in Phase 2 Small molecular drug [55]
RBx10558 DMYSADI Discontinued in Phase 2 NA [56]
RP-64477 DMTQ3BS Discontinued in Phase 2 NA [57]
SCH-48461 DM28AFU Discontinued in Phase 2 Small molecular drug [58]
SKF-97426 DM40HTZ Discontinued in Phase 2 NA [59]
Sodelglitazar DMJ816F Discontinued in Phase 2 Small molecular drug [60]
Tiqueside DMUJ2X6 Discontinued in Phase 2 Small molecular drug [61]
Torcetrapib DMDHYM7 Discontinued in Phase 2 Small molecular drug [62]
447C88 DMC7M3K Discontinued in Phase 1 NA [63]
AVP-26452 DMML3PA Discontinued in Phase 1 NA [64]
DRF 10945 DMOPM7L Discontinued in Phase 1 NA [65]
E-3030 DMJWR1I Discontinued in Phase 1 NA [66]
ETC-1001 DM43SLA Discontinued in Phase 1 NA [67]
MKC-121 DMKHR28 Discontinued in Phase 1 NA [68]
S-16961 DMEU2F4 Discontinued in Phase 1 Small molecular drug [69]
YM-17E DM0FSA9 Discontinued in Phase 1 Small molecular drug [70]
YM-750 DMLD2R0 Discontinued in Phase 1 Small molecular drug [71]
BMY-22089 DMZFTLK Terminated Small molecular drug [73]
CLX-0900 DMYPRS9 Terminated NA [74]
Lecimibide DMFEMTG Terminated Small molecular drug [75]
RP-70676 DMHO5AG Terminated NA [76]
SQ-33600 DMT5LX0 Terminated Small molecular drug [77]
------------------------------------------------------------------------------------
⏷ Show the Full List of 39 Drug(s)
This Disease is Treated as An Indication in 1 Preclinical Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
MAHDL01 DMUWP4O Preclinical NA [72]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 13 Investigative Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
4'-GALACTOSYLLACTOSE DMRF9NH Investigative Small molecular drug [78]
ARM-AK-105 DMYCABR Investigative NA [78]
Campestanol ascorbyl phosphate DM0CUTX Investigative NA [78]
DW-816 DMD7DHO Investigative NA [78]
HE2200 DMMSG6A Investigative NA [78]
HL-029 DMTA71I Investigative NA [78]
HL-162 DMV8QC1 Investigative NA [78]
HL-4130 DMJZF16 Investigative NA [78]
LM-13765 DM90D4K Investigative NA [78]
PJ-015 DMIDQHH Investigative NA [78]
WIB-901H DMXTXTI Investigative NA [78]
WS-070117 DMYNIG5 Investigative NA [79]
YJRN-0904 DMUQEPC Investigative NA [78]
------------------------------------------------------------------------------------
⏷ Show the Full List of 13 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2668).
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2950).
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3439).
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5 Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
6 Vitamin E: tocopherols and tocotrienols as potential radiation countermeasures. J Radiat Res. 2013 Nov 1;54(6):973-88.
7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8400).
8 ClinicalTrials.gov (NCT00658515) A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome. U.S. National Institutes of Health.
9 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004370)
10 ClinicalTrials.gov (NCT00519714) A Study to Evaluate the Lipid Regulating Effects of 1-Methylnicotinamide (1-MNA). U.S. National Institutes of Health.
11 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6529).
12 ClinicalTrials.gov (NCT02100839) Safety Study of AEM-28 to Treat Refractory Hypercholesterolemia. U.S. National Institutes of Health.
13 Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta. 2011 May; 1808(5): 1290-1308.
14 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002276)
15 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003592)
16 Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase. Expert Opin Investig Drugs. 2000 Jul;9(7):1635-49.
17 ClinicalTrials.gov (NCT00293878) Study on the Safety and Effects on Lipids of FM-VP4 in Subjects With Primary Hypercholesterolemia. U.S. National Institutes of Health.
18 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024296)
19 ClinicalTrials.gov (NCT00929539) Safety and Efficacy Study of JTT-130 in Obese Type 2 Diabetic Patients. U.S. National Institutes of Health.
20 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8470).
21 NO-1886 (ibrolipim), a lipoprotein lipase activator, increases the expression of uncoupling protein 3 in skeletal muscle and suppresses fat accumulation in high-fat diet-induced obesity in rats. Metabolism. 2005 Dec;54(12):1587-92.
22 ClinicalTrials.gov (NCT00080132) Implitapide in Patients With Hypertriglyceridemia (HTG) on Maximal, Concurrent Triglyceride-Lowering Therapy. U.S. National Institutes of Health.
23 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
24 ClinicalTrials.gov (NCT00879112) Study of MB07811 in Subjects With Hypercholesterolemia. U.S. National Institutes of Health.
25 Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-beta agonist. Atherosclerosis. 2013 Oct;230(2):373-80.
26 Inhibition of ileal Na+/bile acid cotransporter by S-8921 reduces serum cholesterol and prevents atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol. 1998 Aug;18(8):1304-11.
27 Efficacy and safety of disodium ascorbyl phytostanol phosphates in men with moderate dyslipidemia. Eur J Clin Pharmacol. 2008 Jul;64(7):651-61.
28 ClinicalTrials.gov (NCT01675154) Phase 2 Study of Orlistat and SLx-4090 for the Treatment of Type 1 Hyperlipoproteinemia. U.S. National Institutes of Health.
29 ClinicalTrials.gov (NCT01970215) TA-8995: Its Use in Patients With Mild Dyslipidaemia (TULIP). U.S. National Institutes of Health.
30 Clinical pipeline report, company report or official report of Luye pharmaceutical.
31 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036391)
32 Bacterial biosensors for screening isoform-selective ligands for human thyroid receptors alpha-1 and beta-1. FEBS Open Bio. 2012; 2: 247-253.
33 Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998 Nov 10;98(19):2088-93.
34 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3440).
35 Clinical pipeline report, company report or official report of ISIS Pharmaceuticals.
36 ClinicalTrials.gov (NCT02208284) A Single Oral Dose Study Of PF-06427878 In Healthy Adult Subjects. U.S. National Institutes of Health.
37 2011 Pipeline of Santaris Pharma.
38 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025892)
39 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001903)
40 ClinicalTrials.gov (NCT00532558) Efficacy of Lapaquistat Acetate on Blood Cholesterol Levels in Treating Subjects With Hypercholesterolemia. U.S. National Institutes of Health.
41 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020608)
42 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002302)
43 Potential role of nonstatin cholesterol lowering agents. IUBMB Life. 2011 Nov;63(11):964-71.
44 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2981).
45 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001196)
46 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004604)
47 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021641)
48 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004427)
49 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011031)
50 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002285)
51 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001230)
52 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018628)
53 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2677).
54 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2678).
55 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000290)
56 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025331)
57 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002301)
58 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002304)
59 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002680)
60 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018093)
61 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002676)
62 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015157)
63 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002257)
64 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015573)
65 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020522)
66 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021476)
67 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017419)
68 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005324)
69 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008215)
70 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002618)
71 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003090)
72 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022420)
73 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2973).
74 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013573)
75 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002283)
76 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002876)
77 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002307)
78 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
79 Alipogene tiparvovec for the treatment of lipoprotein lipase deficiency. Drugs Today (Barc). 2013 Mar;49(3):161-70.
80 ClinicalTrials.gov (NCT01294683) A Study to Evaluate Efficacy and Safety of Extended-Release Niacin (+) Laropiprant (+) Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118). U.S. National Institutes of Health.
81 ClinicalTrials.gov (NCT01674712) A 12-week Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate/Simvastatin 145/20mg and Fenofibrate/Simvastatin 145/40mg Tablets Versus Fenofibrate or Simvastatin Monotherapies in Subjects With Abnormal Blood Levels of Fats (Lipids) and at High Risk of Cardiovascular Disease. U.S. National Institutes of Health.
82 Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov. 2003 Jul;2(7):517-26.